Alvogen is lined up to copy 2 of the blockbuster drugs on this tracker, which earned $24.2B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Alvogen's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Ozempic | Novo Nordisk | Generic | 2032 | Settled, terms confidential | ≈$19.3B |
| Imbruvica | AbbVie / Johnson & Johnson | Generic | 2032 | Blocked by court ruling (2021) | $4.9B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Alvogen's share of it.